Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

636
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
636
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

732
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early complications and long-term outcome of patients treated with a Subcutaneous Cardioverter-Defibrillator: temporal trends and clinical implications of the anesthetic strategies adopted at implant.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Safety and performance of a novel ICD lead for left bundle branch area pacing: Results from the ASCEND CSP trial.

Heart rhythm·2026
Same author

The HONEST Cohort Study: Rationale and Design of a Nationwide Subcutaneous Implantable Cardioverter-Defibrillator Cohort.

JACC. Advances·2026
Same author

Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.

JACC. Clinical electrophysiology·2026
Same author

Catheter Ablation of atrial fibrillation vs. atrioventricular nodal ablation with Conduction system pacing in persistent atrial fibrillation and heart failure (ABACUS): rationale and design.

European heart journal open·2026

Related Experiment Video

Updated: Mar 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Avoiding non-responders to cardiac resynchronization therapy: a practical guide.

Claude Daubert1,2, Nathalie Behar3, Raphaël P Martins1,2,3

  • 1School of medicine, Rennes 1 University, Rennes, France.

European Heart Journal
|July 3, 2016
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) benefits only 70% of heart failure patients. Overcoming non-response requires multidisciplinary collaboration to optimize device programming and patient management.

Keywords:
Cardiac resynchronization therapyHeart failureLeft bundle branch blockTherapeutic responseVentricular remodelling

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Related Experiment Videos

Last Updated: Mar 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Clinical Electrophysiology

Background:

  • Cardiac resynchronization therapy (CRT) is a key treatment for drug-refractory heart failure (HF).
  • Approximately 30% of patients do not respond to CRT, a significant clinical challenge.
  • The multifactorial nature of non-response (NR) necessitates a comprehensive approach.

Purpose of the Study:

  • To review endpoints used in CRT clinical trials and their impact on response rates.
  • To identify factors contributing to CRT non-response.
  • To provide recommendations for optimizing CRT and preventing non-response.

Main Methods:

  • Critical review of landmark clinical trials for CRT endpoints and response variability.
  • Analysis of different investigational designs, patient populations, and therapy delivery methods.
  • Discussion of device programming, telemonitoring, and heart failure management strategies.

Main Results:

  • Variability in CRT response rates is linked to diverse trial designs, patient selection, and therapy delivery.
  • Potentially reversible causes of NR, such as loss of biventricular pacing due to arrhythmias, are highlighted.
  • Optimizing device settings and patient management can improve CRT efficacy.

Conclusions:

  • Addressing CRT non-response requires standardized definitions, technological advancements, and improved therapy delivery.
  • Multidisciplinary collaboration among heart failure teams, electrophysiologists, and cardiac imaging experts is crucial.
  • Preventing CRT non-response enhances treatment effectiveness and improves the risk-benefit ratio for heart failure patients.